Kraj: Indonezja
Język: indonezyjski
Źródło: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
SILDENAFIL CITRATE
PFIZER INDONESIA - Indonesia
SILDENAFIL CITRATE
14.045 MG
SIRUP KERING
DUS, 1 BOTTLE @ 112 ML
FAREVA AMBOISE - France
2019-07-31
Generic Name: Sildenafil Citrate Trade Name: Revatio CDS Effective Date: May 23, 2017 Supersedes: NA 2018-0037193 Page 1 of 26 PT. PFIZER INDONESIA LOCAL PRODUCT DOCUMENT Generic Name: Sildenafil Citrate Trade Name: Revatio CDS Effective Date: May 23, 2017 Supersedes: NA 1. NAME OF THE MEDICINAL PRODUCT 1.1. PRODUCT NAME Revatio 1.2. STRENGTH 10 mg/mL 1.3. PHARMACEUTICAL DOSAGE FORM White to off-white powder for oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1. QUALITATIVE DECLARATION After reconstitution, each mL of the oral suspension contains 10 mg of sildenafil (as citrate). Following reconstitution, the volume of suspension is 112 mL containing 1.12 g of sildenafil (as citrate), providing a usable volume of 90 mL of suspension at a sildenafil concentration of 10 mg/mL, adequate to provide a 30 day supply of a 10 mg dose, or a 15 day supply of a 20 mg dose. 2.2. QUANTITATIVE DECLARATION Each mL of oral suspension contains 250 mg sorbitol. For excipients, see section 6.1. 3. PHARMACEUTICAL FORM White to off-white powder. Once reconstituted, white to off-white opaque fluid containing undissolved solids. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Pediatric Population Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Posology: _Pediatric population (1 year to 17 years)_ DISETUJUI BPOM: 18/07/2019 ID: EREG10024111900019 Generic Name: Sildenafil Citrate Trade Name: Revatio CDS Effective Date: May 23, 2017 Supersedes: NA 2018-0037193 Page 2 of 26 For pediatric patients aged 1 year to 17 years old, the recommended dose in patients ≤20 kg is 10 mg (1 mL of compounded suspension) three times a day and for patients >20 kg is 20 mg (2 mL of compounded suspension) three times a day. Higher than recommended dos Przeczytaj cały dokument